SCI Pain App Intervention Study

Sponsor
Baylor College of Medicine (Other)
Overall Status
Terminated
CT.gov ID
NCT04818814
Collaborator
The University of Texas Health Science Center, Houston (Other), TIRR Memorial Hermann (Other)
11
1
2
4.8
2.3

Study Details

Study Description

Brief Summary

The purpose of this study is to find out if using an app is a feasible and acceptable treatment for chronic pain in persons with spinal cord injury. Participants will have a 50% chance of being asked to listen to 10 minutes of audio-guided meditations using an app each day for six weeks, and a 50% chance of being asked to listen to 10 minutes of engaging and distracting presentations about topics of interest to the individual (TED Talks) for six weeks. All participants will be asked to complete three online surveys about their emotional and physical health lasting 20-30 minutes (one when the participant first enters the study, one six weeks later, and another six weeks later). Additionally, participants will be asked to complete brief (<5 minute) online surveys once a week during the first six weeks of their participation. Participation in this study is very low risk, and participants may not experience any personal benefit from their participation. Participation in this study is entirely voluntary.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Mindfulness Meditation App
  • Behavioral: Engagement and Distraction App
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
11 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
SCI Pain App Intervention Study
Actual Study Start Date :
Oct 4, 2021
Actual Primary Completion Date :
Feb 28, 2022
Actual Study Completion Date :
Feb 28, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Mindfulness Meditation (MM) App

Participants randomized to the MM condition will be asked to download and use the free Mindfulness Coach app (available for iOS and Android platforms) developed by the Veteran Affairs National Center for PTSD. The app offers written information about mindfulness as well as 12 audio-guided meditations each lasting 8-13 minutes. Participants will attend a live videochat orientation to the study with the research coordinator (RC) to receive assistance in downloading and using the app. Participants will be asked to listen to at least one, and ideally two, audio-guided meditation exercises using the app daily for six weeks. The RC will ask participants to complete weekly logs of their MM app use via a Qualtrics survey sent via email.

Behavioral: Mindfulness Meditation App
Listening to audio-guided meditation sessions using a mobile app.

Active Comparator: Engagement and Distraction (ED) App

Participants randomized to the Engagement and Distraction condition will be asked to download and use the free TED Talk app (available for iOS and Android platforms). The app offers many videos of engaging and distracting presentations about technology, entertainment, and design. The research coordinator will work with the participant to create a customized list of Ted Talk videos, each lasting 6-12 minutes, based on participants' personal interests. Participants will be asked to listen to or watch at least one, and ideally two, presentations using the app daily for six weeks. The research coordinator will ask participants to complete weekly logs of their TED Talk app use via a Qualtrics survey sent via email.

Behavioral: Engagement and Distraction App
Listening to engaging and distracting videos of interest to the participant using a mobile app.

Outcome Measures

Primary Outcome Measures

  1. Feasibility of Daily Practice as assessed by the proportion of assigned home practice completed [Immediately post-intervention (i.e., 6-weeks post-baseline)]

    proportion of assigned home practice completed by participants

  2. Feasibility of Immediate Post-Intervention Follow-Up Assessment as assessed by the proportion of participants who complete immediate post-intervention follow up assessment [Immediately post-intervention (i.e., 6-weeks post-baseline)]

    proportion of participants who complete immediate post-intervention follow up assessment

  3. Feasibility of 6-Week Follow-Up Assessment as assessed by the proportion of participants who complete 6 weeks post-intervention follow up assessment [6 weeks post-intervention (i.e., 12-weeks post-baseline)]

    proportion of participants who complete 6 weeks post-intervention follow up assessment

  4. Participant Satisfaction as assessed by a satisfaction questionnaire adapted from the Client Satisfaction Questionnaire for Internet-based Interventions (CSQ-I) [Immediately post-intervention (i.e., 6-weeks post-baseline)]

    participant reported satisfaction with their assigned condition; scores range from 12-48, with higher scores indicating greater satisfaction

Secondary Outcome Measures

  1. International SCI Pain Basic Data Subset Questionnaire [Immediately post-intervention (i.e., 6-weeks post-baseline) and 6 weeks post-intervention (i.e., 12-weeks post-baseline)]

    Self-reported pain intensity and interference on a 0-10 scale with higher scores indicating greater pain intensity and interference

  2. Chronic Pain Acceptance Questionnaire [Immediately post-intervention (i.e., 6-weeks post-baseline) and 6 weeks post-intervention (i.e., 12-weeks post-baseline)]

    Self-reported acceptance of pain; scores range from 0-156 with higher scores indicating greater acceptance of pain

  3. Five Facet Mindfulness Questionnaire-Short Form [Immediately post-intervention (i.e., 6-weeks post-baseline) and 6 weeks post-intervention (i.e., 12-weeks post-baseline)]

    Self-reported mindfulness; scores range from 24-120 with higher scores indicating greater mindfulness

  4. Patient Health Questionnaire-8 item [Immediately post-intervention (i.e., 6-weeks post-baseline) and 6 weeks post-intervention (i.e., 12-weeks post-baseline)]

    Depressive Symptoms; scores range from 0-24 with higher scores indicating greater depression symptoms

  5. Generalized Anxiety Disorder Questionnaire-7 [Immediately post-intervention (i.e., 6-weeks post-baseline) and 6 weeks post-intervention (i.e., 12-weeks post-baseline)]

    Anxiety Symptoms; scores range from 0-21 with higher scores indicating greater anxiety symptoms

  6. SCI-QOL Positive Affect and Wellbeing Questionnaire [Immediately post-intervention (i.e., 6-weeks post-baseline) and 6 weeks post-intervention (i.e., 12-weeks post-baseline)]

    Self-reported Quality of Life; scores range from 10-50 with higher scores indicating greater quality of life

Other Outcome Measures

  1. Patient Health Questionnaire-2 item [Assessed weekly during the 6-week intervention]

    Depressive Symptoms; scores range from 0-6 with higher scores indicating greater depression symptoms

  2. Generalized Anxiety Disorder Questionnaire-2 [Assessed weekly during the 6-week intervention]

    Anxiety Symptoms; scores range from 0-6 with higher scores indicating greater anxiety symptoms

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. are at least 18 years of age

  2. have a traumatic SCI of at least 6 months duration

  3. have chronic pain [defined as pain lasting at least 3 months with a pain intensity rating of 4 or higher on a 10-point visual analog scale]

  4. understand spoken and written English sufficiently to understand the goals, procedures, time involved, and the time involved in participation, participate in the intervention and complete study surveys.

Exclusion Criteria:
  1. have a significant visual or hearing impairment that limits their ability to participate in the app/computer-based intervention

  2. lack access to and the ability to use a smart phone or smart tablet (e.g., iPad)

  3. are unable to provide or obtain an email address for communication

  4. practiced any kind of meditation more than once a week in the past 3 months

Contacts and Locations

Locations

Site City State Country Postal Code
1 TIRR Memorial Hermann Houston Texas United States 77030

Sponsors and Collaborators

  • Baylor College of Medicine
  • The University of Texas Health Science Center, Houston
  • TIRR Memorial Hermann

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Susan Robinson Whelen, Principal Investigator, Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT04818814
Other Study ID Numbers:
  • H-47556
First Posted:
Mar 26, 2021
Last Update Posted:
Apr 6, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 6, 2022